Adderley Nicola, Nirantharakumar Krishnarajah, Marshall Tom
Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
Institute of Applied Health Research, University of Birmingham, Birmingham, UK
BMJ Open. 2019 Nov 21;9(11):e030454. doi: 10.1136/bmjopen-2019-030454.
To investigate whether the introduction of performance targets for anticoagulation in atrial fibrillation (AF) was associated with a change in use of the 'resolved AF' code.
Retrospective cohort studies.
Data from The Health Improvement Network, a UK database of electronic patient records, from 2000 to 2016.
250 788 adult patients aged ≥18 years with a diagnosis of AF, including 14 757 with an incident diagnosis of 'resolved AF'.
Annual and monthly incidence of 'resolved AF' from 2000 to 2016. Among patients with 'resolved AF', for each year we calculated median duration of the preceding AF diagnosis and the proportion prescribed anticoagulants prior to 'resolved AF'.
Incidence of 'resolved AF' increased from 5.7 to 26.3 per 1000 person-years between 2005 and the introduction of AF performance targets in 2006. Compared with the years prior to the introduction of the performance targets, incidence has remained higher in every year since their implementation. Since 2007, monthly incidence has been highest between January and March. Between 2005 and 2006, median duration between AF and 'resolved AF' diagnoses increased from 276 days (9 months) to 1343 days (3 years 8 months). Among 'resolved AF' patients with CHADS-VASc score ≥1, 81.9% (95% CI 81.1 to 82.6) had no current anticoagulant prescription, and 62.3% (95% CI 61.4 to 63.2) had no record of any anticoagulant prescription.
The introduction of AF performance targets was followed by a large increase in use of the 'resolved AF' code, particularly in the months immediately before practices make their anticoagulant performance target submissions. Although most AF patients are prescribed anticoagulants, few patients diagnosed with 'resolved AF' are prescribed anticoagulants and most have never been prescribed them. Untreated patients are much more likely to be coded as having 'resolved AF'.
研究房颤(AF)抗凝治疗绩效目标的引入是否与“已缓解房颤”代码的使用变化相关。
回顾性队列研究。
来自英国电子病历数据库“健康改善网络”2000年至2016年的数据。
250788名年龄≥18岁且诊断为房颤的成年患者,其中14757例为首次诊断为“已缓解房颤”。
2000年至2016年“已缓解房颤”的年发病率和月发病率。在“已缓解房颤”患者中,我们计算了每年房颤诊断前的中位持续时间以及“已缓解房颤”前开具抗凝剂的比例。
2005年至2006年引入房颤绩效目标期间,“已缓解房颤”的发病率从每1000人年5.7例增加到26.3例。与引入绩效目标之前的年份相比,自实施以来每年的发病率一直较高。自2007年以来,月发病率在1月至3月最高。2005年至2006年,房颤与“已缓解房颤”诊断之间的中位持续时间从276天(9个月)增加到1343天(3年8个月)。在CHADS-VASc评分≥1的“已缓解房颤”患者中,81.9%(95%CI 81.1至82.6)目前未开具抗凝剂,62.3%(95%CI 61.4至63.2)没有任何抗凝剂处方记录。
房颤绩效目标引入后,“已缓解房颤”代码的使用大幅增加,尤其是在医疗机构提交抗凝治疗绩效目标之前的几个月。虽然大多数房颤患者都开具了抗凝剂,但很少有诊断为“已缓解房颤”的患者开具抗凝剂,且大多数患者从未开具过。未接受治疗的患者更有可能被编码为“已缓解房颤”。